Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Open-label, Non-randomized, Single-arm, Multi-center Dose Titration Study to Investigate the Safety and Efficacy of NT 201 in Subjects Deemed to Require Total Body Doses of 800 U of NT 201 During the Course of the Study for the Treatment of Upper and Lower Limb Spasticity of the Same Body Side Due to Cerebral Causes

Next Previous
Trial Profile

Prospective, Open-label, Non-randomized, Single-arm, Multi-center Dose Titration Study to Investigate the Safety and Efficacy of NT 201 in Subjects Deemed to Require Total Body Doses of 800 U of NT 201 During the Course of the Study for the Treatment of Upper and Lower Limb Spasticity of the Same Body Side Due to Cerebral Causes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Muscle spasticity
  • Focus Adverse reactions; Registrational
  • Acronyms TOWER
  • Sponsors Merz Pharmaceuticals GmbH

    • Most Recent Events

    • 08 Jun 2017 Results of a post-hoc analysis evaluating the effectiveness of incobotulinumtoxinA for treating lower limb (LL) spasticity, presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.
    • 08 Jun 2017 Results of a post-hoc analysis assessing efficacy of botulinum toxin for shoulder spasticity presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 28 Apr 2017 Results of post-hoc analysis (n=109) assessing the effectiveness of incobotulinumtoxinA for treating key clinical patterns of lower limb spasticity, presented at the 69th Annual Meeting of the American Academy of Neurology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top